article thumbnail

STAT+: FTC warns drugmakers they can face legal action over improper patent listings

STAT

The Federal Trade Commission warned pharmaceutical companies they could face legal action if they improperly list patents for brand-name medicines in a Food and Drug Administration registry, the latest effort by the federal government to scrutinize patent moves by drugmakers.

article thumbnail

STAT+: Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal

STAT

government to remove the key negotiator working on a free trade agreement with the Indian government because of his previous ties to a major pharmaceutical company. More than 200 civil society and patient advocacy groups are urging the U.K. Now, the groups are upset that the involvement of Harjinder Kang, the U.K.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How global healthcare partners and Indian pharma companies are contributing to affordable medicines

Express Pharma

As the world’s leading supplier of generic drugs, India’s pharmaceutical industry has become a ray of hope for millions as it ensures quality-assured and cost-effective treatments reach those who need them the most.

Vaccines 102
article thumbnail

The Guardian view on India-UK trade talks: don’t make it harder for the health service | Editorial

The Guardian - Pharmaceutical Industry

Britain is pushing for patent changes that could increase the cost of Indian generic drugs, diverting more of the NHS budget to big pharma India is known as the “ pharmacy of the world ”, supplying vital generic medicines at low prices to health services including the NHS. They spend billions on research and recoup billions.

article thumbnail

CHMP meeting highlights: February 2024

European Pharmaceutical Review

Medicine indication extensions recommended by the CHMP The committee recommended extensions of indications for six EU-approved medicines, including: CARVYKTI ® ▼ (ciltacabtagene autoleucel; cilta-cel)* , Keytruda and Reblozyl*. These products were designated as an orphan medicine during their development.

article thumbnail

The critical role of the generics sector during the pandemic

pharmaphorum

During this time, the role and responsibility of generics suppliers and manufacturers has been brought into stark perspective as one of the leading contributors in this industry-wide effort. The pandemic has further highlighted how research is not strictly limited to large, “innovator” pharmaceutical companies.

article thumbnail

Only 2 per cent medicines undergo quality control checks: Former IMA President

Express Pharma

Krishna Sarma, Managing Partner, Corporate Law Group , said, “The entanglement of Registered Medical Practitioners (RMPs) in third-party activities involving pharmaceutical companies, coupled with the haze surrounding generic medicines, beckons for clarity.